GluA4-targeted AAV Vectors Deliver Genes Selectively to Interneurons While Relying on the AAV Receptor for Entry
Molecular Therapy - Methods and Clinical Development - United States
doi 10.1016/j.omtm.2019.07.004
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2019
Authors
Publisher
Elsevier BV